Home
Contact Us
Site Map
Skip to content
About PDL
About PDL
PDL History
Management
Board of Directors
Dividend FAQs
Careers
Contact Us
Technology & Products
Technology & Products
What are Antibodies?
How do Antibodies Work?
What are Humanized Monoclonal Antibodies?
Monoclonal Antibody Therapy
Commercialized Products
Product Pipeline
Royalty Revenue
Royalty Revenue
Historical Product Sales Revenue
Historical Royalty Revenue
Manufacturing Split Genentech / Roche & Novartis
Investor Relations
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
SEC Filings
Stock Information
Investor FAQs
Proxy Materials
Contact Us
News & Resources
News & Resources
News Releases
Company Presentations & Events
Quarterly Investor Update
Site Map
About PDL
PDL History
Management
John McLaughlin
Christopher L. Stone
Danny Hart
Board of Directors
Jody Lindell
John McLaughlin
Paul Sandman
Harold Selick, Ph.D.
Dividend FAQs
Careers
Contact Info
Technology & Products
What are Antibodies?
How do Antibodies Work?
What are Humanized Monoclonal Antibodies?
Monoclonal Antibody Therapy
Commercialized Products
Avastin
®
(bevacizumab)
Herceptin
®
(trastuzumab)
Lucentis
®
(ranibizumab)
Xolair
®
(omalizumab)
Tysabri
®
(natalizumab)
Synagis
®
(palivizumab)
Mylotarg
®
(gemtuzumab ozogamicin)
Actemra
®
/RoActemra (tocilizumab)
Product Pipeline
Bapineuzumab
Solanezumab
Motavizumab
Teplizumab
Trastuzumab-DM1
Royalty Revenue
Historical Product Revenue
Historical Royalty Revenue
Manufacturing Split – Genentech/Roche
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
SEC Filings
Stock Information
Investor FAQs
Proxy Materials
Shareholder Briefcase Registration
Receive Printed Materials Signup
Email Alerts Signup
Download Library
RSS Feeds
News & Resources
News Releases
Company Presentations & Events
Quarterly Investor Update
Comments are closed.
